Invokana MDL timeline.
Invokana MDL Timeline
Multidistrict Litigation (MDL) over Janssen Pharmaceuticals’ diabetes drug Invokana continues to make its way through federal court in New Jersey, with case management conferences scheduled to take place throughout the summer and fall of 2018. The most recent case management conference was held on June 7 and the next is calendared for July 19.
As of the most recently available Case Management Order, issued in January 2018, the court reported that 1,001 separate cases had been filed in the MDL, with a total of 902 complaints having been served.
The MDL was created in December 2016 by order of the Judicial Panel on Multidistrict Litigation, which transferred the cases to the New Jersey district court.
Plaintiffs accuse Janssen of failing to adequately warn of Invokana’s risk of amputation, which subsequently has been determined to be serious enough to warrant a Black Box Warning from the US Food and Drug Administration (FDA), the agency’s highest level of warning.
According to its official website, Invokana helps those suffering from type 2 diabetes maintain lower blood sugar levels.
In a case management conference for the Invokana MDL, a federal district court in New Jersey confirmed its expectation that the first trial would begin sometime around September 2018. As of the date of the conference, the 1001 cases involving 902 different complainants had been filed as part of the MDL.
A Pennsylvania federal court sided with defendants Janssen and Johnson & Johnson when it rejected plaintiffs’ request to return their cases to the Court of Common Pleas in Philadelphia as part of a mass tort action. The move brought the pharmaceutical companies one step closer to their goal of consolidating the Pennsylvania state court cases with the MDL in New Jersey federal court. Following its victory, Johnson & Johnson released a statement that read in part, “With real-world experience that includes more than 10 million prescriptions to date, we are confident in the overall safety profile of Invokana.”
Defendant Janssen Pharmaceutical filed a motion requesting that over 100 Invokana-related cases that plaintiffs had brought against the company in the Court of Common Pleas of Philadelphia be removed to federal district court in New Jersey as part of the recently approved MDL there.
Immediately following approval of the federal MDL, plaintiffs in 87 Invokana-related cases requested that a Philadelphia County judge combine their cases into a mass tort, arguing that doing so would streamline the judicial process and result in more consistent rulings. In their filings, plaintiffs alleged that sales of Invokana totaled in excess of $1 billion annually.
A collection of plaintiffs suing Johnson & Johnson and Janssen Pharmaceuticals over acute kidney damage allegedly caused by Invokana issued a request to the Judicial Panel on Multidistrict Litigation (JPML) in Miami asking that the panel consolidate their cases in multidistrict litigation (MDL) to be heard before a federal court in New Jersey. The initial MDL request covered 56 cases in 11 districts. Later in the month, the JPML granted plaintiffs’ request for consolidation.
Plaintiff Arthur Portnoff filed suit against Janssen Pharmaceuticals in the Court of Common Pleas in Philadelphia, alleging that his use of Invokana as a treatment for type 2 diabetes had caused his diabetic ketoacidosis. Portnoff further claimed that Janssen had been aware of serious harms associated Invokana but had withheld material information from the FDA and failed to warn patients adequately. Portnoff’s suit came just days after the FDA issued a revised Invokana label that included a new warning about the risk of ketoacidosis. In a prepared statement, a Janssen spokeswoman said, “With real world experience that includes more than five million prescriptions to date, we are confident in the overall safety profile of Invokana.”
US District Court – District of New Jersey MDL No. 2750 – In Re: Invokana (canagliflozin) Products Liability Litigation Case Management Order #25
Legal Disclaimer: The information in this article is not intended to be used as medical information or diagnosis. The sources of the information presented in the article have been researched and are linked within the article. Please seek out medical advice from a licensed medical professional if you are experiencing a problem with any of the drugs or devices mentioned in this article.
About The Law Firm
TheLawFirm.com is a group of award winning attorneys, paralegals and associates from the legal profession who’s main goal is to educate and represent their clients with the utmost expertise, respect and trust.
We also work closely with a large group of experts from the medical profession so we can draw upon their expertise, in order to present as much accurate information relating to various mass tort and personal injury lawsuits as we can.